Director of hematology department at Beijing Children’s Hospital , China.
Dr. Runhui Wu is a distinguished expert in pediatric hematology, serving as the Director of the Hematology Department at Beijing Children’s Hospital, Capital Medical University, China. With over three decades of experience, Dr. Wu has made significant contributions to the management and treatment of hemophilia and other bleeding disorders in children. She has played a pivotal role in establishing comprehensive care programs for hereditary coagulation disorders and pediatric immune thrombocytopenia (ITP) in China. Her research focuses on individualized prophylaxis for severe hemophilia, immunologic tolerance in hemophilia, and the genetic diagnosis of coagulation factor deficiencies. Dr. Wu’s extensive publication record, leadership in national and international collaborative efforts, and numerous awards, including the Chinese Medical Science and Technology Award, highlight her impact on advancing pediatric hematology. Her work has significantly improved the quality of life for children with bleeding disorders, making her a leading figure in her field.
Profile
Dr. Runhui Wu’s educational journey is rooted in a deep commitment to medical excellence, beginning with her Bachelor’s degree in Medicine from Capital Medical University, completed in 1991. She continued her advanced studies at the same institution, earning a Master’s degree in Medicine in 2005. Dr. Wu’s pursuit of knowledge culminated in a Doctor of Medicine (M.D.) degree from Capital Medical University in 2011. Throughout her academic journey, Dr. Wu honed her expertise in hematology, laying the foundation for her future contributions to the field. Her education, marked by rigorous training and a passion for pediatric hematology, has played a pivotal role in shaping her distinguished career, enabling her to lead innovative research and clinical advancements in the treatment of hemophilia and other blood disorders in children.
Professional Experience
Dr. Runhui Wu is a distinguished hematologist and Director of the Hematology Department at Beijing Children’s Hospital, Capital Medical University. With an extensive career dedicated to pediatric hematology, Dr. Wu has significantly contributed to the management and treatment of hemophilia and other hereditary coagulation disorders. She has been instrumental in establishing specialized outpatient clinics for hemophilia in children, creating a comprehensive treatment team that has gained national recognition. Her leadership extends to directing the pediatric group of the Hemophilia Treatment Center Collaborative Network of China (HTCCNC) and serving as the Associated Director of the Hematology Department at China’s Commission of Health. Additionally, Dr. Wu has been a key figure in national and international research collaborations, focusing on individualized prophylaxis in children with severe hemophilia A. Her work has led to the publication of numerous peer-reviewed articles and significant advancements in pediatric hematology care in China.
Research Interest
Dr. Runhui Wu’s research interests primarily focus on pediatric hematology, with a specific emphasis on hemophilia and other bleeding disorders. Her work explores the genetic diagnosis, pathogenesis, and prevention of coagulation factor deficiencies in children. Dr. Wu is particularly interested in individualized prophylactic treatments for severe hemophilia A, aiming to improve patients’ quality of life and reduce complications associated with the disease. She has also conducted significant research in pediatric immune thrombocytopenia (ITP), investigating novel therapeutic approaches and exploring the underlying mechanisms of the disease. Her contributions extend to the development of guidelines for the diagnosis and treatment of pediatric hematological disorders in China, reflecting her commitment to advancing both clinical practice and scientific knowledge in this field. Dr. Wu’s research is deeply intertwined with her dedication to improving healthcare outcomes for children with rare and complex blood disorders.
Dr. Runhui Wu possesses exceptional research skills in the field of pediatric hematology, with a focus on hemophilia and related bleeding disorders. His expertise spans genetic diagnosis, pathogenesis, and the development of innovative treatment strategies, particularly in the realm of individualized prophylaxis for children with severe hemophilia A. Dr. Wu has demonstrated proficiency in leading multidisciplinary research teams and securing significant funding for pioneering studies. His research contributions include exploring the role of immune tolerance in hemophilia and investigating the mechanisms of inhibitor development. Additionally, Dr. Wu has a strong publication record in top-tier journals, reflecting his ability to conduct rigorous scientific research and translate findings into clinical practice. His work has significantly advanced the understanding and management of pediatric hematological disorders, earning him recognition both nationally and internationally. Dr. Wu’s dedication to research and his collaborative approach have positioned him as a leader in the field of pediatric hematology.
Awards and Recognition
Dr. Wu has received multiple awards, including the Shanghai Science and Technology Award and the Chinese Medical Science and Technology Award. These accolades recognize her outstanding contributions to medical research and her influence on improving healthcare practices in China.
Conclusion
In conclusion, Dr. Runhui Wu is a strong candidate for the Best Researcher Award due to her extensive contributions to pediatric hematology, significant impact on healthcare practices in China, and her collaborative efforts in both national and international research. Her work has led to tangible improvements in patient care, making her a deserving recipient of this prestigious recognition.
Publications Top Notes
- A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)
- Authors: Yao, W., Ai, D., Zhang, Q., Luke, K.-H., Wu, R.
- Year: 2024
- Surgical procedures and complications in placement of totally implantable venous access port in pediatric hemophilia patients: A retrospective analysis
- Authors: Cheng, W., Zhang, J., Wang, X., Wu, R., Li, Z.
- Year: 2024
- The Differences of Serum Thrombopoietin Levels Between Acquired Aplastic Anemia and Immune Thrombocytopenia in Pediatric Patients
- Authors: Chen, H., Ma, J., Ouyang, J., Wu, R., Chen, Z.
- Year: 2024
- Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China
- Authors: Xu, Y., Wang, Y., Wu, R., Xue, F., Yang, R.
- Year: 2024
- The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China
- Authors: Hu, Y., Wang, Z., Ma, J., Cheng, X., Wu, R.
- Year: 2024
- FOXO1 Single-Nucleotide Polymorphisms Are Associated with Bleeding Severity and Sensitivity of Glucocorticoid Treatment of Pediatric Immune Thrombocytopenia
- Authors: Xie, X., Gu, H., Ma, J., Wu, R., Chen, Z.
- Year: 2024
- Clinical characteristics of eosinophilic lung diseases in children | 儿童肺嗜酸性粒细胞增多症的临床特征研究
- Authors: Xu, X., Yin, J., Liu, J., Wu, R., Xu, B.
- Year: 2024
- Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL
- Authors: Li, Z., Sun, J., Li, Z., Poon, M.-C., Wu, R.
- Year: 2024
- Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China
- Authors: Wang, Z., Zhang, A., Xu, Z., Cheng, X., Wu, R.
- Year: 2024
- Citations: 1
- HIF-1α induced by hypoxic condition regulates Treg/Th17 axis polarization in chronic immune thrombocytopenia
- Authors: Gu, H., Wang, Z., Xie, X., Wu, R., Chen, Z.
- Year: 2024